Skip to content

Study · Randomized controlled trial · n = 67 · 2008

3 results

Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study.

Lee HW, Lee JI, Um SH, Ahn SH, Chang HY, Park YK, Hong SP, Moon YM, Han KH

Journal of gastroenterology and hepatology1 May 2008Cited by 17 (Europe PMC)

PMID18410608 (opens in a new tab)DOI10.1111/j.1440-1746.2008.05387.x (opens in a new tab)PepBankPUB-18410608
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In HBeAg-positive adults with chronic hepatitis B, adding thymosin alpha‑1 to lamivudine gave more HBeAg seroconversion at 24 weeks than lamivudine alone (26.5% vs 6.1%, P = 0.024).

    In plain wordsIn adults with HBeAg-positive chronic hepatitis B, adding thymosin alpha‑1 to lamivudine gave more HBeAg seroconversion at 24 weeks than lamivudine alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseHBeAg seroconversion at 24 weeks
    Study

    n = 67

    Comparator
    Lamivudine monotherapy
    Outcome group
    Antiviral activity · Liver
    Studied dose
    1.6 mg twice a week · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    HBeAg seroconversion
    26.5%
    combination group, week 24
    HBeAg seroconversion
    6.1%
    lamivudine monotherapy, week 24

    Source sentences

    Summary
    The incidence of HBeAg seroconversion at 24 weeks was 26.5% (9/34) in the combination group and 6.1% (2/33) in the monotherapy group (P = 0.024).
    1 context sentence
    Summary · context
    Sixty-seven patients were assigned to two different groups in a randomized manner. The combination group (n = 34) received Talpha1 (1.6 mg subcutaneously, twice a week) and lamivudine (100 mg orally, daily) for 24 weeks, followed by continuous lamivudine therapy. The monotherapy group (n = 33) recei…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In HBeAg-positive adults with chronic hepatitis B, HBeAg seroconversion at 52 weeks did not differ significantly between thymosin alpha‑1 plus lamivudine and lamivudine alone (26.5% vs 12.1%, P = 0.138).

    In plain wordsIn adults with HBeAg-positive chronic hepatitis B, HBeAg seroconversion at 52 weeks was not significantly different with thymosin alpha‑1 plus lamivudine than with lamivudine alone.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeHBeAg seroconversion at 52 weeks
    Study

    n = 67

    Comparator
    Lamivudine monotherapy
    Outcome group
    Antiviral activity · Liver
    Studied dose
    1.6 mg twice a week · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    HBeAg seroconversion
    26.5%
    combination group, week 52
    HBeAg seroconversion
    12.1%
    lamivudine monotherapy, week 52

    Source sentences

    Summary
    However, there was no statistically significant difference between 26.5% (9/34) in the combination group and 12.1% (4/33) in the monotherapy group at 52 weeks (P = 0.138).
    1 context sentence
    Summary · context
    Sixty-seven patients were assigned to two different groups in a randomized manner. The combination group (n = 34) received Talpha1 (1.6 mg subcutaneously, twice a week) and lamivudine (100 mg orally, daily) for 24 weeks, followed by continuous lamivudine therapy. The monotherapy group (n = 33) recei…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In HBeAg-positive adults with chronic hepatitis B, viral breakthrough at 52 weeks did not differ significantly between thymosin alpha‑1 plus lamivudine and lamivudine alone (35.3% vs 21.2%, P = 0.201).

    In plain wordsIn adults with HBeAg-positive chronic hepatitis B, viral breakthrough at 52 weeks was not significantly different with thymosin alpha‑1 plus lamivudine than with lamivudine alone.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeViral breakthrough at 52 weeks
    Study

    n = 67

    Comparator
    Lamivudine monotherapy
    Outcome group
    Antiviral activity · Liver
    Studied dose
    1.6 mg twice a week · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Viral breakthrough
    35.3%
    combination group, week 52
    Viral breakthrough
    21.2%
    lamivudine monotherapy, week 52

    Source sentences

    Summary
    The emergence of viral breakthrough gradually increased to 35.3% (12/34) in the combination group, and to 21.2% (7/33) in the monotherapy group at 52 weeks (P = 0.201).
    1 context sentence
    Summary · context
    Sixty-seven patients were assigned to two different groups in a randomized manner. The combination group (n = 34) received Talpha1 (1.6 mg subcutaneously, twice a week) and lamivudine (100 mg orally, daily) for 24 weeks, followed by continuous lamivudine therapy. The monotherapy group (n = 33) recei…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.